INNOVENT BIO (01801) released its interim results, with a profit of 1.253 billion yuan, a year-on-year increase of 50.2%.

INNOVENT BIO (01801) announced its interim results for the six months ending June 30, 2026, measured in accordance with International Financial Reporting Standards (IFRS): total revenue of 8.618 billion yuan (RMB, the same below), an increase of 44.8% year-on-year; profit for the period of 1.253 billion yuan, an increase of 50.2% year-on-year; basic earnings per share of 0.73 yuan. The announcement stated that in the first half of 2026, the company's revenue accelerated growth, profit scale continued to expand, cash on hand was abundant, multiple large international collaborations were realized, and more pipelines demonstrated global valuethese solid advancements give us reason to believe that INNOVENT BIO is in the best development window since its establishment. Based on this foundation, over the next five to ten years, we hope to complete a third critical transformationfrom a domestically leading biopharmaceutical company to an internationally first-class biopharmaceutical enterprise with preliminary multinational operational capabilities. Our commercial product portfolio includes 20 approved products: Daboshu (sintilimab injection), Dayoutong (bevacizumab injection), Suliximab (adalimumab injection), Dabohua (rituximab injection), Dabotan (pemigatinib tablets), Nailike (alpelisib tablets), Xiranze (lemolizumab), Ruituo (sepafenib capsules), Fukesu (ikigairolin injection), Xinbile (toripalimab injection), Dabote (furazolidone tablets), Daboer (dihydroergotamine tartrate capsules), Jiepalire (pimozide tablets), Ao Yixin (lercapresin tablets), Xinbimin (tengrestat N01 injection), Xinermei (masitidine injection), Xinmeiyue (pikamilon injection), Daboxin (ipilimumab N01 injection), Weize (abemaciclib tablets), and Weifutai (quzartinib tablets). Among our products, 13 have been included in the National Reimbursement Drug List (NRDL). In the first half of 2026, the company achieved total revenue of 8.618 billion yuan, with product revenue of 8.202 billion yuan, representing year-on-year increases of 44.8% and 56.7%, respectively. This strong performance is attributed to the effective implementation of the company's dual-engine growth strategy, the accelerated release of contributions from the comprehensive pipeline business, and the continuous growth of products newly included in the NRDL for oncology pipelines. According to IFRS, net profit increased by 50.2% year-on-year to 1.253 billion yuan; Non-IFRS net profit grew by 40.5% year-on-year to 1.704 billion yuan, with the robust profit growth primarily benefiting from rapid revenue expansion and continuous improvement in operational efficiency. The operational results for the first half of 2026 not only confirm the company's improving operational situation but also mark the company's entry into a new stage where revenue and profit quality are increasing simultaneously, steadily advancing towards the goal of becoming an "international first-class biopharmaceutical enterprise."